Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Oncolytics Bio TSX: ONC-T

Today's Change
Volume
Real-Time Last Update TSX Last Sale

Today's Trading

Day Low 3.30
Day High 3.51
Open:3.35
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Oncolytics Biotech Inc is a development stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The company's product pipeline includes Bavencio, Keytruda, Opdivo, Retifanlimab, and Tecentriq.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Strong Buy

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference
- PR Newswire - PRF - Thu May 13, 6:00AM CDT
PR Newswire - PRF - CMTX
Thu May 13, 6:00AM CDT
and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference, which is taking place virtually from . Presentation details are listed below.Dr. Matt Coffey, President & Chief Executive Officer of Oncolytics Biotech Inc.
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
- CNW Group - Mon May 10, 6:00AM CDT
CNW Group - CMTX
Mon May 10, 6:00AM CDT
COMTEX_386258164/2669/2021-05-10T07:00:54
Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results
- CNW Group - Fri May 7, 6:00AM CDT
CNW Group - CMTX
Fri May 7, 6:00AM CDT
Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 3.13 +9.58% increase
on 05/17/21
Period Open:3.72
Price movement based on the high, low and last over the given period.
3.91 -12.28% decrease
on 04/22/21
-0.29 (-7.80%) decrease
since 04/16/21
3-Month 3.04 +12.83% increase
on 03/05/21
Period Open:4.40
Price movement based on the high, low and last over the given period.
6.06 -43.40% decrease
on 04/08/21
-0.97 (-22.05%) decrease
since 02/18/21
52-Week 2.00 +71.50% increase
on 09/04/20
Period Open:2.89
Price movement based on the high, low and last over the given period.
6.06 -43.40% decrease
on 04/08/21
+0.54 (+18.69%) increase
since 05/15/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies